Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation
Targets Protein Linked To Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome is one of the prime causes behind the mounting global death toll of COVID-19, but there are currently no FDA-approved treatments. Armed with biomarker and genotyping assays, Aqualung hopes to speed its antibody candidate into development by next year.
You may also be interested in...
Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.